Lilly looks eastward with generics deal

Eli Lilly ($LLY) is reportedly in early talks with Turkish generics maker Mustafa Nevzat Ilac Sanayii AS, also known as MN. The talks possibly concern a partnership or investment.

A union of the two would give Lilly access to the low-cost product manufacturing, local distribution and regulatory expertise MN has in place, reports the Wall Street Journal. Turkey also serves a gateway to Asia.

MN makes generic antibiotics and would enjoy an expansive Western distribution network.

The Indianapolis drug giant recently reaped the benefits of a tie-up with Boehringer Ingelheim in a disease--rather than geographic--market deal. The collaborators are targeting diabetes and last month earned European regulatory approved for linagliptin, one of several late-stage diabetes drugs in mid- and late-stage development.

- here's the story

Suggested Articles

Cadila Healthcare is looking for outside manufacturing partners to add 70 million doses of its experimental COVID-19 vaccine to its arsenal.

The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.